The FDA approved Novartis's ribociclib for the first-line treatment of hormone receptor (HR)+/HER2− advanced breast cancer in combination with an aromatase inhibitor. This is the second approval for the cyclin-dependent kinase 4 and 6 (CDK4/6) class of kinase inhibitors.CDKs

中文翻译：

---

FDA批准诺华的CDK4 / 6抑制剂

FDA批准了诺华的ribociclib与激素酶抑制剂联合用于激素受体（HR）+ / HER2-晚期乳腺癌的一线治疗。这是细胞周期蛋白依赖性激酶4和6（CDK4 / 6）类激酶抑制剂的第二次批准。